ShannonNeville(Neville)WestinMD

Obstetrics & Gynecology • Houston, TX

Gynecologic Oncology

Associate Professor Dept of Gynecologic Oncology and Reproductive Medicine

Join to view full profile

Dr. Westin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Westin's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 2006 - 2010
University of North Carolina HospitalsResidency, Obstetrics and Gynecology, 2002 - 2006
University of Florida College of MedicineClass of 2002

Certifications & Licensure

FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2027
GA State Medical License 2023 - 2026
TN State Medical License 2023 - 2026
TX State Medical License 2008 - 2026
AL State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
OK State Medical License 2020 - 2025
WA State Medical License 2023 - 2025
NC State Medical License 2002 - 2007
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology
Join now to see all

Clinical Trials

Laparoscopic Approach to Cervical Cancer Start of enrollment: 2008 Jan 01
Completed
Not Applicable
Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer Start of enrollment: 2008 Nov 03
ACTIVE_NOT_RECRUITING
PHASE2
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer Start of enrollment: 2010 Aug 19
ACTIVE_NOT_RECRUITING
PHASE1
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer Start of enrollment: 2012 Sep 01
Completed
Phase 1
Biospecimen Collection in Assessing the Effect of Trametinib With or Without Uprosertib on Biomarkers in Patients With Persistent or Recurrent Endometrial Cancer Enrolled on Trial GOG02290 Start of enrollment: 2004 Aug 13
Completed
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Start of enrollment: 2014 Nov 11
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Adavosertib Before Surgery in Treating Patients with Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2016 Feb 04
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer Start of enrollment: 2016 Aug 24
COMPLETED
PHASE2
Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) Start of enrollment: 2016 Jul 06
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Selumetinib and Olaparib in Solid Tumors Start of enrollment: 2017 Aug 04
ACTIVE_NOT_RECRUITING
PHASE1
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2019 Apr 29
ACTIVE_NOT_RECRUITING
PHASE1
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery Start of enrollment: 2019 Jun 07
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer Start of enrollment: 2020 May 05
ACTIVE_NOT_RECRUITING
PHASE3
Prediction of Recurrence Among Low Risk Endometrial Cancer Patients Start of enrollment: 2012 Nov 08
ACTIVE_NOT_RECRUITING
EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors Start of enrollment: 2015 Jul 01
ACTIVE_NOT_RECRUITING
PHASE1
Roles: Principal Investigator, Contact
TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Start of enrollment: 2021 Dec 14
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
Roles: Principal Investigator, Contact
Etigilimab and Nivolumab for the Treatment of Platinum-Resistant Recurrent Clear Cell Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2021 Oct 01
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2018 Dec 07
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer Start of enrollment: 2015 Sep 23
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator, Contact
EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer Start of enrollment: 2023 Mar 24
RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer Start of enrollment: 2023 Jul 12
RECRUITING
PHASE1
Roles: Principal Investigator, Contact
A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary Start of enrollment: 2022 Dec 09
Terminated
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Folate Receptor Immunohistochemical Staining and Gynecologic Tumors: Initial Experience With 216 Cases.
Barrett C Lawson, Mario L Marques-Piubelli, Shannon N Westin, Anais Malpica
International Journal of Gynecological Pathology. 2025-03-01
Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.
Amma Asare, Rebecca Ann Previs, Daniel Spinosa, Bryan Fellman, Amelia L Scott
Gynecologic Oncology. 2025-02-22
Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial.
Jeffrey A How, Minghao Dang, Sanghoon Lee, Bryan Fellman, Shannon N Westin
Med. 2025-01-10

Journal Articles

Prospective Phase II Trial of Levonorgestrel Intrauterine Device: Non-Surgical Approach for Complex Atypical Hyperplasia and Early Endometrial Cancer
Shannon N Westin, Lois M Ramondetta, Kathleen M Schmeler, Pamela T Soliman, Nicole D Fleming, Jennifer K Burzawa, Alpa M Nick, Andrea M Milbourne, Diane C Bodurka, Rob..., American Journal of Obstetrics and Gynecology

Lectures

Risk factors for progression or death in ovarian cancer patients who completed first-line platinum treatment.
2019 ASCO Annual Meeting - 6/1/2019
Phase I trial of olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
Tumor Sequencing: Who, What, When, and Why to Order Tumor Mutation Analysis
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Authored Content

Prospective Phase II Trial of Levonorgestrel Intrauterine Device: Non-Surgical Approach for Complex Atypical Hyperplasia and Early Endometrial CancerAugust 2020
Prospective Phase II Trial of Levonorgestrel Intrauterine Device: Non-Surgical Approach for Complex Atypical Hyperplasia and Early Endometrial CancerAugust 2020

Press Mentions

Ovarian Cancer Test May Miss Black and Native American PatientsMarch 21st, 2025
Ovarian Cancer Blood Test Misses Some Black, Native American PatientsMarch 20th, 2025
Delta Plane That Flipped over in Toronto Last Month Showed High Rate of Descent, Initial Report SaysMarch 20th, 2025
Join now to see all